Tempest Therapeutics Valuation
| TPST Stock | USD 2.31 0.02 0.86% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Tempest Therapeutics has a current Real Value of $4.46 per share. The regular price of the company is $2.31. Our model measures the value of Tempest Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 8.19 %, shares outstanding of 4.93 M, and Return On Equity of -4.05 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Tempest Therapeutics' valuation include:
Undervalued
Today
Please note that Tempest Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Tempest Therapeutics is based on 3 months time horizon. Increasing Tempest Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Tempest Therapeutics' intrinsic value may or may not be the same as its current market price of 2.31, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.31 | Real 4.46 | Target 11.0 | Hype 2.22 |
The intrinsic value of Tempest Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tempest Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tempest Therapeutics helps investors to forecast how Tempest stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tempest Therapeutics more accurately as focusing exclusively on Tempest Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Tempest Therapeutics' intrinsic value based on its ongoing forecasts of Tempest Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Tempest Therapeutics' closest peers.
Tempest Therapeutics Cash |
|
Tempest Therapeutics Total Value Analysis
Tempest Therapeutics is at this time projected to have valuation of 12.47 M with market capitalization of 11.48 M, debt of 15.37 M, and cash on hands of 51.62 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tempest Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.47 M | 11.48 M | 15.37 M | 51.62 M |
Tempest Therapeutics Asset Utilization
One of the ways to look at asset utilization of Tempest is to check how much profit was generated for every dollar of assets it reports. Tempest Therapeutics has a negative utilization of assets of -0.89 %, losing $0.008932 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tempest Therapeutics shows how discouraging it operates for each dollar spent on its assets.Tempest Therapeutics Profitability Analysis
Based on Tempest Therapeutics' profitability indicators, Tempest Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Tempest Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2011-09-30 | Previous Quarter -7.9 M | Current Value -3.5 M | Quarterly Volatility 5.3 M |
For Tempest Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tempest Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tempest Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tempest Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tempest Therapeutics over time as well as its relative position and ranking within its peers.
Tempest Therapeutics Earnings per Share Projection vs Actual
By analyzing Tempest Therapeutics' earnings estimates, investors can diagnose different trends across Tempest Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Tempest Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Tempest Therapeutics Ownership Allocation
The market capitalization of Tempest Therapeutics is $11.48 Million. About 91.78 % of Tempest Therapeutics outstanding shares are held by general public with 0.03 (%) owned by insiders and only 8.19 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Tempest Therapeutics Profitability Analysis
Net Loss for the year was (41.84 M) with profit before overhead, payroll, taxes, and interest of 0.About Tempest Therapeutics Valuation
The stock valuation mechanism determines Tempest Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Tempest Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tempest Therapeutics. We calculate exposure to Tempest Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tempest Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -350.1 K | -367.6 K | |
| Pretax Profit Margin | (329.74) | (346.23) | |
| Operating Profit Margin | (79.85) | (83.84) | |
| Net Loss | (329.71) | (346.20) | |
| Gross Profit Margin | 0.81 | 0.86 |
Tempest Therapeutics Current Valuation Indicators
Tempest Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Tempest Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Tempest Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Tempest Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Tempest Therapeutics' worth.Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.